

# INCIDENCE OF FUNGAL INFECTIONS IN PATIENTS TREATED WITH IXEKIZUMAB

Poster number:  
5PSQ-068

N. BÁEZ GUTIÉRREZ, H. RODRÍGUEZ RAMALLO, C. GALLEGO MUÑOZ, M. MEJIAS TRUEBA, M. SORIANO MARTÍNEZ. HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO, PHARMACY, SEVILLE, SPAIN.

## Background and importance

Candida infections have been reported on pivotal trials of antibody agents against IL-17 such as ixekizumab. However, there is little evidence in real-world patients.

## Aim and objectives


To evaluate the incidence of candida infection in adults treated with ixekizumab.

## Material and methods

Retrospective observational study of patients treated with ixekizumab from January 2017 until December 2018 in a third level hospital.


Data collected: demographics, indication, previous therapies, ixekizumab treatment duration, amount of candidiasis risk factors (>65 years, obesity, DM2), nº of patients who developed candidiasis, time on treatment before developing candidiasis.

## Results



## Conclusion and relevance

- When comparing with ixekizumab pivotal trials (UNCOVER trials) the incidence of Candida infection was found to be increased by a small degree in real-world patients (3.3% vs 6.6%).
- Patients undergoing such treatment should be monitored for fungal infection and treated as necessary.



<https://www.eahp.eu/25-5PSQ-068>

References and/or acknowledgements Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017 Jul;177(1):47-62.